Cellis has created its macrophage–drug conjugate (MDC) platform to overcome the challenges. “The MDC platform presents a highly novel cell-therapy approach that can be delivered in an ...

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

Temporomandibular joint (TMJ) osteoarthritis is a degenerative, debilitating and progressive disease, the second most common musculoskeletal ...

These findings open new doors for macrophage-based therapies, which could enhance myocardial repair without relying on ...

This study provides proof-of-principle data for the use of trained immunity to modulate macrophage interactions with tumours. The study makes a valuable contribution to the field of trained immunity.

After a year of stripping back its head count and pipeline, Carisma Therapeutics is now cutting down to the bone and laying ...

Bregenholt hopes that with this approach Macrophage, and its lead product MPL5821, could help pharma to overcome some of the issues that still dog checkpoint inhibitor therapy. While these drugs ...

Many other signals (both secreted chemicals and cell-cell surface interactions) also control the outcome of interaction between macrophages and T cells. These may be important targets for medical ...

The macrophages also showcased morphological changes. “Looking at the world of cancer immunology and cell therapy, it is largely driven by biology. However, in addition to the biology of the cell, it ...

Greenwich Lifesciences Inc. followed a February update with another on the phase III Flamingo-01 trial, providing open-label immune response data for GLSI-100, a HER2/neu peptide vaccine immunotherapy ...